FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer


Dr Gilbert discusses the FDA approval of dostarlimab in patients with endometrial cancer, key efficacy data from the GARNET trial, and how this agent bolsters the endometrial cancer treatment paradigm.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Lucy Gilbert, MD, MSc, about the FDA approval of dostarlimab-gxly (Jemperli) in patients with endometrial cancer. Dr Gilbert is a professor in the Department of Obstetrics and Gynecology and a professor in the Department of Oncology at McGill University, as well as director of Gynecologic Oncology and director of the Women’s Health Research Unit at McGill University and McGill University Health Centre in Montreal, Canada.

On February 9, 2023, the FDA granted regular approval to dostarlimab for adult patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial cancer with disease progression on or after platinum-containing therapies in any setting who are not eligible for radiation or curative surgery. This regulatory decision follows the April 2021 accelerated approval of the agent in this population.

The regular approval was backed by findings from the phase 1 GARNET trial (NCT02715284), in which the cohort of patients with dMMR endometrial cancer achieved a confirmed objective response rate of 45.4% with dostarlimab. Additionally, in the endometrial cancer cohort, the median duration of response was not reached, 85.9% of patients had responses lasting at least 1 year, and 54.7% of patients had responses lasting at least 2 years.

In our exclusive interview, Dr Gilbert discussed the significance of this approval, key efficacy data from GARNET, and how this agent bolsters the endometrial cancer treatment paradigm.


That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Maurie Markman, MD
Salman R. Punekar, MD
Bhavana Pothuri, MD
David M. O’Malley, MD
Suresh Ramalingam, MD, and Chandler Park, MD
Amin Nassar, MD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center